Eli Lilly Q3 2026: Sales Surge 39% as Acquired R&D Weighs on Profit Growth

Eli Lilly’s third-quarter income statement shows rapid sales growth—but a much smaller increase in profit as spending on acquired drug research surged. Digging into its Q3 2026 10-Q helps explain that gap and what it reveals about the pharmaceutical company’s business: diabetes and obesity medicines are funding substantial investment in its next generation of treatments.

Revenue reached $24.4 billion, up 39% from a year earlier. Net income rose 16% to $6.45 billion, while diluted earnings per share increased to $7.22 from $6.21.

Two medicines drive nearly all the growth

Lilly sells treatments across diabetes, obesity, cancer, immunology, and neuroscience, but its growth remains heavily concentrated in two tirzepatide brands:

• Mounjaro: Revenue increased 65% to $10.72 billion.
• Zepbound: Revenue increased 49% to $5.35 billion.

Together, they generated 66% of total revenue, versus 57% a year earlier. Their combined $6.0 billion sales increase accounted for approximately 88% of Lilly’s overall revenue increase.

That concentration matters. Oncology revenue grew a more modest 8% to $2.6 billion, while Trulicity and Taltz sales declined 14% and 5%, respectively.

International expansion also stood out. Revenue outside the U.S. rose 47% to $9.26 billion, outpacing 34% U.S. growth. Mounjaro alone generated $5.73 billion outside the U.S.—more than its domestic sales.

However, growth came despite considerable pricing pressure. Lilly’s revenue bridge attributes 53 percentage points of growth to volume, offset by a 15-point drag from price, with rounding affecting the reported total. Outside the U.S., the price drag reached 29 points. The central takeaway: Lilly is expanding sales through volume, not higher realized prices.

Strong gross margins meet a large research bill

The quarterly revenue-to-profit flow shows where the money went:

Gross profit increased 40% to $20.46 billion, and gross margin improved to 83.9% from 82.9%. Routine research and development rose 23% to $4.25 billion, while marketing, selling, and administrative expenses increased 14% to $3.13 billion—both slower than revenue.

The major difference was acquired in-process research and development, which jumped to $4.18 billion from $656 million. These are charges for purchased research programs that have not yet become approved products.

Two transactions explain most of that expense:

• $2.61 billion related to AtaiBeckley’s BPL-003, a Phase 2 treatment for treatment-resistant depression.
• $954 million related to Curevo’s Phase 2 shingles vaccine, amezosvatein.

Calculated operating income rose approximately 17% to $8.61 billion, but operating margin fell to 35.3% from 41.8%. Acquired research charges alone absorbed 17% of quarterly revenue. Thus, slower profit growth does not reflect deteriorating gross margins; it primarily reflects a much larger expense for purchasing future pipeline opportunities.

Cash generation is strong, but commitments are substantial

For the first nine months, operating cash flow reached $27.42 billion, roughly double the prior year. Yet investing outflows totaled $27.61 billion, including acquisitions, purchased research, and $8.44 billion of capital spending. Debt increased $7.0 billion to $49.5 billion.

Lilly’s results show a highly profitable business reinvesting aggressively. In competition with companies such as Novo Nordisk, the key issues are increasingly volume, access, and pipeline execution. With two medicines supplying two-thirds of revenue, pricing pressure and product concentration remain important counterweights to impressive growth.